Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 8, 2019. The document serves as a transaction notification regarding dealings in the company's ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Exercise of Share Options and Subsequent Sale |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Volume | 6,910 Shares |
| Exercise Price | £11.7700 |
| Sale Price | £15.6941 |
| Transaction Date | February 7, 2019 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a routine insider transaction involving the Company Secretary.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a share option exercise and sale.
Key Facts for Investor Verification
- The transaction involved Mrs. V A Whyte, the Company Secretary.
- 6,910 ordinary shares were exercised from options granted on February 17, 2009.
- The shares were immediately sold on the London Stock Exchange (XLON) at £15.6941 per share.
- The exercise price was £11.7700 per share.
- The filing does not contain any financial results or strategic updates for the company.